18kDa陽(yáng)離子抗菌肽(CAMP)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法)
ELISA Kit for Cathelicidin Antimicrobial Peptide (CAMP)
CAP18; FALL39; HSD26; LL37; 18 kDa Cationic Antimicrobial Protein; Antibacterial protein FALL-39; FALL-39 peptide antibiotic
- 編號(hào)SEC419Hu
- 物種Homo sapiens (Human，人)相同的名稱，不同的物種。
- 實(shí)驗(yàn)方法雙抗夾心
- 反應(yīng)時(shí)長(zhǎng)3h
- 檢測(cè)范圍0.78-50ng/mL
- 靈敏度最小可檢測(cè)劑量小于等于0.27ng/mL.
- 樣本類型serum, plasma and other biological fluids
- 下載英文說(shuō)明書(shū) 中文說(shuō)明書(shū)
- 規(guī)格48T96T96T*596T*1096T*100
- 價(jià)格¥ 3570¥ 5100¥ 22950¥ 43350¥ 357000
- 欲了解實(shí)際交易價(jià)格和更多情況，請(qǐng)與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
產(chǎn)品包裝(模擬)
產(chǎn)品包裝(模擬)
實(shí)驗(yàn)結(jié)果圖
標(biāo)準(zhǔn)曲線圖
通過(guò)ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
本試劑盒用于檢測(cè)18kDa陽(yáng)離子抗菌肽(CAMP)，經(jīng)檢測(cè)與其它相似物質(zhì)無(wú)明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來(lái)源的限制，不可能完成對(duì)所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測(cè)，因此本試劑盒有可能與未經(jīng)檢測(cè)的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的18kDa陽(yáng)離子抗菌肽(CAMP)（加標(biāo)樣品），重復(fù)測(cè)定并計(jì)算其均值，回收率為測(cè)定值與理論值的比率。
| 樣本 | 回收率范圍(%) | 平均回收率(%) |
| serum(n=5) | 89-103 | 98 |
| EDTA plasma(n=5) | 95-103 | 99 |
| heparin plasma(n=5) | 79-92 | 88 |
精密度
精密度用樣品測(cè)定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差：取同批次試劑盒對(duì)低、中、高值定值樣本進(jìn)行定量檢測(cè),每份樣本連續(xù)測(cè)定20 次，分別計(jì)算不同濃度樣本的平均值及SD值。
批間差：選取3個(gè)不同批次的試劑盒分別對(duì)低、中、高值定值樣本進(jìn)行定量測(cè)定，每個(gè)樣本使用同一試劑盒重復(fù)測(cè)定8次，分別計(jì)算不同濃度樣本的平均值及SD值。
批內(nèi)差： CV<10%
批間差： CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的18kDa陽(yáng)離子抗菌肽(CAMP)，并倍比稀釋成1:2，1:4，1:8，1:16的待測(cè)樣本，線性范圍即為稀釋后樣本中18kDa陽(yáng)離子抗菌肽(CAMP)含量的測(cè)定值與理論值的比率。
| 樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 78-92% | 88-95% | 96-103% | 91-101% |
| EDTA plasma(n=5) | 80-103% | 92-105% | 89-105% | 80-93% |
| heparin plasma(n=5) | 80-102% | 87-96% | 95-104% | 99-105% |
穩(wěn)定性
經(jīng)測(cè)定，試劑盒在有效期內(nèi)按推薦溫度保存，其活性降低率小于5%。
為減小外部因素對(duì)試劑盒破壞前后檢測(cè)值的影響，實(shí)驗(yàn)室的環(huán)境條件需盡量保持一致，尤其是實(shí)驗(yàn)室內(nèi)溫度、濕度及溫育條件。其次由同一實(shí)驗(yàn)員來(lái)進(jìn)行操作可減少人為誤差。
實(shí)驗(yàn)流程
1. 實(shí)驗(yàn)前標(biāo)準(zhǔn)品、試劑及樣本的準(zhǔn)備；
2. 加樣（標(biāo)準(zhǔn)品及樣本）100µL，37°C孵育1小時(shí)；
3. 吸棄，加檢測(cè)溶液A100µL，37°C孵育1小時(shí)；
4. 洗板3次；
5. 加檢測(cè)溶液B100µL，37°C孵育30分鐘；
6. 洗板5次；
7. 加TMB底物90µL，37°C孵育10-20分鐘；
8. 加終止液50µL，立即450nm讀數(shù)。
實(shí)驗(yàn)原理
將18kDa陽(yáng)離子抗菌肽(CAMP)抗體包被于96孔微孔板中，制成固相載體，向微孔中分別加入標(biāo)準(zhǔn)品或標(biāo)本，其中的18kDa陽(yáng)離子抗菌肽(CAMP)與連接于固相載體上的抗體結(jié)合，然后加入生物素化的18kDa陽(yáng)離子抗菌肽(CAMP)抗體，將未結(jié)合的生物素化抗體洗凈后，加入HRP標(biāo)記的親和素，再次徹底洗滌后加入TMB底物顯色。TMB在過(guò)氧化物酶的催化下轉(zhuǎn)化成藍(lán)色，并在酸的作用下轉(zhuǎn)化成最終的黃色。顏色的深淺和樣品中的18kDa陽(yáng)離子抗菌肽(CAMP)呈正相關(guān)。用酶標(biāo)儀在450nm波長(zhǎng)下測(cè)定吸光度(O.D.值)，計(jì)算樣品濃度。
贈(zèng)品
增值服務(wù)
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種：Homo sapiens (Human，人) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| RPC419Hu01 | 18kDa陽(yáng)離子抗菌肽(CAMP)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| CPC419Hu21 | 18kDa陽(yáng)離子抗菌肽(CAMP)卵白蛋白偶聯(lián)物 | Immunogen; SDS-PAGE; WB. |
| PAC419Hu02 | 18kDa陽(yáng)離子抗菌肽(CAMP)多克隆抗體 | WB; IHC; ICC; IP. |
| PAC419Hu01 | 18kDa陽(yáng)離子抗菌肽(CAMP)多克隆抗體 | WB; IHC; ICC; IP. |
| PAC419Hu08 | 18kDa陽(yáng)離子抗菌肽(CAMP)多克隆抗體 | WB; IHC; ICC; IP. |
| LAC419Hu71 | 18kDa陽(yáng)離子抗菌肽(CAMP)多克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
| MAC419Hu22 | 18kDa陽(yáng)離子抗菌肽(CAMP)單克隆抗體 | WB; IHC; ICC; IP. |
| MAC419Hu28 | 18kDa陽(yáng)離子抗菌肽(CAMP)單克隆抗體 | WB |
| MAC419Hu21 | 18kDa陽(yáng)離子抗菌肽(CAMP)單克隆抗體 | WB |
| SEC419Hu | 18kDa陽(yáng)離子抗菌肽(CAMP)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| CEC419Hu | 18kDa陽(yáng)離子抗菌肽(CAMP)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| LMC419Hu | 18kDa陽(yáng)離子抗菌肽(CAMP)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
| KSC419Hu11 | 18kDa陽(yáng)離子抗菌肽(CAMP)檢測(cè)試劑盒DIY材料(酶聯(lián)免疫吸附試驗(yàn)法) | Main materials for "Do It (ELISA Kit) Yourself". |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| University of Waikato | The Assessment of Vitamin D, Antimicrobial Peptides and Procalcitonin in Bronchiectasis[Waikato:Source] |
| Clin Infect Dis. | Host immune response to tuberculous meningitis[Pubmed:25301213] |
| Vaccine | On birth single dose live attenuated OPV and BCG vaccination induces gut cathelicidin LL37 responses at 6 week of age: A natural experiment[Pubmed:25444792] |
| Urology | Modulating the Internalization of Bacille Calmette-Guérin by Cathelicidin in Bladder Cancer Cells [Pubmed:25681250] |
| Urology | Modulating the Internalization of Bacille Calmette-Guérin by Cathelicidin in Bladder Cancer Cells[PubMed: 25681250] |
| Sarcoidosis Vasc Diffuse Lung Dis | Cathelicidin as a link between sarcoidosis and tuberculosis[PubMed: 26422567] |
| Allergy and Asthma Proceedings | The association of vitamin D, cathelicidin, and vitamin D binding protein with acute asthma attacks in children[PubMed: 26108071] |
| J Clin Microbiol. | Swiftly Decreasing Cerebrospinal Fluid Cathelicidin Concentration Predicts Improved Outcome in Childhood Bacterial Meningitis.[Pubmed:27008883] |
| experimental dermatology | Light-emitting diodes downregulate cathelicidin, kallikrein and toll-like receptor 2 expressions in keratinocytes and rosacea-like mouse skin.[pubmed:27315464] |
| PLOS?ONE | Reduced?Expression?of the?Extracellular?Calcium-Sensing?Receptor?(CaSR) Is?Associated?withActivation?of the?Renin-Angiotensin?System?(RAS) to Promote Vascular Remodeling in the Pathogenesis of Essential Hypertension.[pubmed:27391973] |
| Front Pharmacol.? | Ginsenoside Rg5 Inhibits Succinate-Associated Lipolysis in Adipose Tissue and Prevents Muscle Insulin Resistance.[pubmed:28261091] |
| Allergologia et immunopathologia | The relation of innate and adaptive immunity with viral-induced acute asthma attacks: Focusing on IP-10 and cathelicidin[pubmed:27955890] |
| Chinese Journal of Osteoporosis and Bone Mineral Research | Effects of cold exposure on the bone marrow adipose tissue[DOI: 10.3969/j.issn.1674-2591.2017.05.008] |
| Scientific Reports | Measurements of AMPs in stratum corneum of atopic dermatitis and healthy skin–tape stripping technique[Pubmed:29374283] |
| Experimental Parasitology | Antimalarial activity of vitamin D3 (VD3) does not result from VD3-induced antimicrobial agents including nitric oxide or cathelicidin[Pubmed: 30904694] |
| Theranostics | Myeloid cell-derived LL-37 promotes lung cancer growth by activating Wnt/β-catenin signaling[Pubmed: 31149039] |
| INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | Short-Term versus Long-Term Culture of A549 Cells for Evaluating the Effects of Lipopolysaccharide on Oxidative Stress, Surfactant Proteins and Cathelicidin LL-37[Pubmed: 32050475] |
| MICROB PATHOGENESIS | Hypovitaminosis D and reduced cathelicidin are strongly correlated during the multidrug therapy against leprosy[Pubmed: 32645421] |
| International Journal of Nanomedicine | Effect of Lonicerae japonicae Flos Carbonisata-Derived Carbon Dots on Rat Models of Fever and Hypothermia Induced by Lipopolysaccharide[Pubmed: 32606669] |
| 博士論文 | Rela??es causais entre a express?o dos genes do receptor de Vitamina D e do Peptídeo Antimicrobiano Catelicidina sobre marcadores sorológicos de pessoas com?…[] |
| PLoS One | Beneficial impact of cathelicidin on hypersensitivity pneumonitis treatment?aIn vivo studies[33999928] |
| New Med | Analysis of the level of non-specific and specific immunity parameters in saliva of children with osteogenesis imperfecta and study of relationships between??-[] |
| Type I interferons link skin-associated dysbiotic commensal bacteria to pathogenic inflammation and angiogenesis in rosacea[] | |
| Int J Mol Sci | Compartmentalized Innate Immune Response of Human Fetal Membranes against Escherichia coli Choriodecidual Infection[Pubmed:35328414] |
| Cell Rep | LL-37 transports immunoreactive cGAMP to activate STING signaling and enhance interferon-mediated host antiviral immunity[Pubmed:35649354] |
